SINOVAC’s overseas revenue rose 82.3% to $66.5 million in the first half of 2026 and reached about 45.2% of total sales, making international markets the primary driver of the vaccine maker’s revenue growth as demand for some products remained pressured in mainland China.
Total first-half sales increased 12.9% to $147.1 million from $130.3 million. The substantially faster international growth means SINOVAC generated approximately $80.6 million of sales outside its overseas business, highlighting how rapidly the company’s geographic revenue mix is changing.
The company said declining births in mainland China continued to weigh on demand for certain vaccines. International markets provided an offset, with higher orders from international organizations supporting particularly strong growth in varicella and poliomyelitis vaccines.
Varicella vaccine sales increased 62.4% to $48.5 million, accounting for approximately one-third of SINOVAC’s total first-half sales, while sales of its Sabin-strain inactivated poliomyelitis vaccine increased 35.3%. A tetanus vaccine that began commercial shipments in December 2025 also added incremental revenue.
The international expansion is extending beyond sales of existing products. SINOVAC secured initial marketing authorizations for products including varicella, hepatitis A and 23-valent pneumococcal polysaccharide vaccines across 12 international markets.
The changing mix also contributed to better gross economics. First-half gross profit increased to $95.5 million from $81.5 million, while gross margin expanded to 65% from 62.5%. SINOVAC attributed the improvement partly to a shift toward higher-margin international products and channels as well as production efficiencies.
The company is also positioning newer products for international commercialization. Its PVRV-SF human rabies vaccine received Chinese marketing approval on August 4 and has been included in a supply agreement under Brazil’s Ministry of Health Productive Development Partnership program. SINOVAC intends to pursue World Health Organization prequalification for the vaccine.
Another potential pipeline catalyst is HFMD2. Its marketing authorization application was accepted for review in July and granted priority-review status, with SINOVAC describing it as having the potential to become the world’s first approved bivalent enterovirus vaccine against hand, foot and mouth disease.
Despite the stronger sales and gross profit, net loss attributable to common shareholders widened to $60.2 million from $21.7 million. Other income dropped sharply to $21.1 million from $161.9 million, while income-tax expense increased to $21.6 million from $0.8 million. Cash, cash equivalents and restricted cash totaled $998.5 million at June 30, compared with $1.2 billion at the end of 2025.
KEY QUOTES:
“In the first half of 2026, SINOVAC delivered steady revenue growth, driven primarily by the sustained expansion of overseas business. Overseas revenue rose 82.3% and accounted for 45.2% of total revenue, demonstrating the continued optimization of our revenue mix under the Company’s globalization strategy. The rabies vaccine for human use (PVRV-SF) received marketing approval from the National Medical Products Administration (NMPA) in August 2026. Developed from the outset with global markets in mind, the vaccine represents an important addition to our commercial portfolio, and we plan to pursue WHO prequalification (WHO PQ) to broaden access to it worldwide. In terms of research and development (R&D), the New Drug Application (NDA) for our bivalent enterovirus vaccine for the prevention of hand, foot and mouth disease (HFMD2) is under official review, and five additional vaccine candidates are currently undergoing Phase III clinical trials. We remain committed to accelerating the global development and commercialization of our innovative pipeline and further strengthening the foundation for sustainable long-term growth.”
Weidong Yin, CEO of SINOVAC
